This article was originally published in The Gray Sheet
Nuclear magnetic resonance technology firm raises $30 mil. in Series B private placement led by Credit Suisse First Boston Private Equity. Funds will go towards developing the San Diego firm's proprietary chemistry technology platform. The device produces high-affinity lead compounds for facilitating small-molecule drug discovery. Investors participating in the round included Skyline Ventures, H&Q Life Science and J&J Development Corp
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.